Phase Forward and Harvard Clinical Research Institute to Jointly Showcase at American College of Cardiology 57th Annual Scientific Conference

Business Wire,  March 25, 2008  

• E-mail
• Print
• Link

Companies to Illustrate Impact of Phase Forward's EDC Technologies on HCRI's Cardiac Device Clinical Trials

WALTHAM, Mass. -- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, and Harvard Clinical Research Institute (HCRI), an academic research organization working with sponsors to advance patient care through world-class clinical research, today announced that the companies will join forces at the 57th annual American College of Cardiology scientific conference ("ACC.08"), March 29-April 1 at McCormick Place in Chicago, Illinois. For additional information on the event, visit: http://acc08.acc.org/Pages/default.aspx.

ACC.08 will bring together nearly 30,000 health care professionals and other attendees from around the world to share best practices and learn about the latest innovations in cardiovascular science and education.

Drawing on their long-standing partnership, Phase Forward and HCRI will team up to showcase their combined capabilities in conducting medical device trials using Phase Forward's electronic data capture (EDC) technologies. Specifically, the companies will provide joint InForm[TM] product demonstrations and HCRI will discuss the impact that this technology has had on the institute's clinical trial development process in the areas of improved speed and accuracy and increased productivity.

The companies will be available at their adjoining booths 22054 and 22052.

Members of the media interested in speaking with Phase Forward or HCRI at the event should contact Meghan Locke at 781-672-3147 or mlocke@chenpr.com.

About Harvard Clinical Research Institute

The Harvard Clinical Research Institute (HCRI) (www.hcri.harvard.edu) designs and manages clinical trials for cutting-edge medical therapies and technologies sponsored by industry-, government-, and clinician-investigators. HCRI's mission is to facilitate greater academic involvement in clinical research. It does so by collaborating with physicians from the Harvard Medical campus, clinical trialists who serve as an integrated resource and assist HCRI in providing clinical resewarch services of the highest quality. The services that HCRI offers include trial design, data management, biostatistics, site management, monitoring, and a suite of clinical event management services including SAE Processing, CEC and DSMB.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm[TM]), phase I clinic automation (LabPas[TM]), clinical data management (Clintrial[TM]), clinical trials signal detection (CTSD[TM]), strategic pharmacovigilance (WebVDME[TM] and Signal Management), adverse event reporting (Empirica[TM] Trace) and applied data standards (WebSDM[TM]). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services, the benefits to a Phase Forward customer from the use of Phase Forward's products and services, and expectations of continued used of Phase Forward's products and services by a customer. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers to realize benefits from the use of its products and services, changes in regulatory requirements applicable to Phase Forward's customers and the manner in which they conduct business, the possibility that customers' needs or plans may change over time, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning